BioSpace News Archive

Specialty cancer diagnostics company Precipio, Inc. announced that due to the increased pathology revenue, and the recent operational efficiencies, the company has reduced the revenue required from the products division to reach breakeven from $8M to $6M annually, or $1.5M per quarter, 25% below previous estimates.

Abdominal Cancers Alliance to provide education and resources to patients, families and physicians surrounding abdominal cancers and CRS/HIPEC procedure

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies

Ascletis Pharma Inc. announces the completion of enrollment of 120 patients in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma.

TransCode Therapeutics, Inc., an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced the pricing of its underwritten public offering of an aggregate of 15,700,000 shares of its common stock.

Immunovant, Inc., a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, announced that it will report initial IMVT-1402 Phase 1 results on Tuesday, September 26, 2023.

Ethris GmbH, a leading biotechnology company pioneering next-generation messenger RNA (mRNA) therapeutics and vaccines, and DIOSynVax, a Cambridge UK based clinical stage biotech spinout specialized in the development of multi-valent vaccine antigen payloads (VAPs), announced today the publication of preclinical proof of concept results for each of their platform technologies in Nature Biomedical Engineering.

Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today that it was awarded a Small Business Technology Transfer (STTR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) division of the National Institute of Health (NIH).

Florence Healthcare, the leading provider of Site Enablement Platforms for clinical trials, announced today that it has acquired VersaTrial, a cutting-edge clinical trial solutions provider.

According to Vision Research Report, the global biosimilar monoclonal antibodies market size was valued at USD 8.76 billion in 2022 and it is projected to hit around USD 65.42 billion by 2032, growing at a CAGR of 22.27% from 2023 to 2032.